Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD

Blood (2019) 134 (Supplement_1): 1958.

https://doi.org/10.1182/blood-2019-128838

Published: 2019

Journal Articles

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

Phuong T. Vo, MD, Ted Gooley, PhD, Joseph G. Rajendran, MD, Darrell R. Fisher, PhD, Johnnie J. Orozco, MD PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Robyn Haaf, BS, Margaret E. Nartea, BS, Rainer F. Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD PhD, John M. Pagel, MD PhD, Brenda M. Sandmaier, MD

Blood (2018) 132 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2018-99-111915

Published: 2018

Journal Articles

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Damian J. Green, Shyril O’Steen, Yukang Lin, Melissa L. Comstock, Aimee L. Kenoyer, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Margaret Nartea, Mark D. Hylarides, Ajay K. Gopal, Theodore A. Gooley, Johnnie J. Orozco, Brian G. Till, Kelly D. Orcutt, K. Dane Wittrup, Oliver W. Press

Blood (2018) 131 (6): 611–620.

https://doi.org/10.1182/blood-2017-09-807610

Published: 2018

Includes: Supplemental data

Journal Articles

Novel Bispecific Antibody Targeting CD45 and 90 Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models

Johnnie J. Orozco, MD PhD, Aimee Kenoyer, BS, Yukang Lin, PhD, Darrell R. Fisher, PhD, Donald K. Hamlin, BS, D. Scott Wilbur, PhD, Alexandra Hernandez, BS, Rosario Guel, Margaret E. Nartea, Shyril O'Steen, PhD, Mark D Hylarides, PhD, Brian G Till, MD, Damian J. Green, MD, Ajay K. Gopal, MD, Kelly D Orcutt, PhD, Karl Dane Wittrup, PhD, Brenda M. Sandmaier, MD, John M. Pagel, MD PhD, Oliver W. Press, MD PhD

Blood (2017) 130 (Supplement 1): 1355.

https://doi.org/10.1182/blood.V130.Suppl_1.1355.1355

Published: 2017

Journal Articles

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

Blood (2017) 130 (Supplement 1): 2048.

https://doi.org/10.1182/blood.V130.Suppl_1.2048.2048

Published: 2017

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

Journal Articles

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

Sherilyn A Tuazon, MD, Brenda M. Sandmaier, MD, Johnnie J. Orozco, MD PhD, Ajay K. Gopal, MD, Leona A. Holmberg, MD PhD, Pamela S. Becker, MD PhD, Sally J. Lundberg, Brian G. Till, MD, Margaret E. Nartea, Ted Gooley, PhD, Darrell R. Fisher, PhD, Joseph G. Rajendran, MD, Oliver W. Press, MD PhD, William I. Bensinger, MD, Damian J. Green, MD

Blood (2017) 130 (Supplement 1): 910.

https://doi.org/10.1182/blood.V130.Suppl_1.910.910

Published: 2017

Journal Articles

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

Blood (2015) 126 (23): 118.

https://doi.org/10.1182/blood.V126.23.118.118

Published: 2015

Journal Articles

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Paul S Martin, MD, Isaac C Jenkins, MS, Theodore A Gooley, PhD, Damian J Green, MD, John M Pagel, MD PhD, Sally J Lundberg, RN, Lacey M Hedine, Joseph G Rajendran, MD, Andrew T Shields, MD, Darrell R Fisher, PhD, David G Maloney, MD PhD, Frederick R Appelbaum, MD, Ryan D Cassaday, MD, Oliver W Press, MD PhD, Ajay K. Gopal, MD

Blood (2015) 126 (23): 5502.

https://doi.org/10.1182/blood.V126.23.5502.5502

Published: 2015

Journal Articles

A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Ryan D. Cassaday, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD, Joseph G. Rajendran, MD, Theodore A. Gooley, PhD, Darrell R. Fisher, PhD, Sally J. Lundberg, Lacey M. Hedin, Andrew T. Shields, MD, Damian J. Green, MD, Robert S. Miyaoka, PhD, Frederick R. Appelbaum, MD, Ajay K. Gopal, MD

Blood (2013) 122 (21): 3333.

https://doi.org/10.1182/blood.V122.21.3333.3333

Published: 2013

Journal Articles

Anti-CD45 radioimmunotherapy using 211 At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model

Johnnie J. Orozco, Tom Bäck, Aimee Kenoyer, Ethan R. Balkin, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Shani L. Frayo, Mark D. Hylarides, Damian J. Green, Ajay K. Gopal, Oliver W. Press, John M. Pagel

Blood (2013) 121 (18): 3759–3767.

https://doi.org/10.1182/blood-2012-11-467035

Published: 2013

Journal Articles

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Raya Mawad, MD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 1924.

https://doi.org/10.1182/blood.V120.21.1924.1924

Published: 2012

Journal Articles

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Ajay K. Gopal, MD, Ted A. Gooley, PhD, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD

Blood (2012) 120 (21): 811.

https://doi.org/10.1182/blood.V120.21.811.811

Published: 2012

Journal Articles

Anti-CD45 Radioimmunotherapy Using the Alpha-Emitting Radionuclide 211 At Combined with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, BS, Tom Bäck, PhD, Ethan R. Balkin, PhD, Donald K. Hamlin, BS, D Scott Wilbur, PhD, Darrell R. Fisher, PhD, Shani L. Frayo, BS, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4096.

https://doi.org/10.1182/blood.V120.21.4096.4096

Published: 2012

Journal Articles

Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, BS, Ethan R. Balkin, PhD, Donald K. Hamlin, BS, D Scott Wilbur, PhD, Darrell R. Fisher, PhD, Shani L. Frayo, BS, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Paul O'Donnell, MD, PhD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4101.

https://doi.org/10.1182/blood.V120.21.4101.4101

Published: 2012

Journal Articles

Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Raya Mawad, MD, Paul O'Donnell, MD, PhD, Ted A. Gooley, PhD, Joseph G Rajendran, MD, Darrell R. Fisher, PhD, Ajay K. Gopal, MD, H. Joachim Deeg, MD, Andrew Shields, MD, Damian J. Green, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 4164.

https://doi.org/10.1182/blood.V120.21.4164.4164

Published: 2012

Journal Articles

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

Johnnie J. Orozco, MD, PhD, Aimee Kenoyer, Amanda Axtman, Shani L. Frayo, BS, Paul J. Morris, Donald K. Hamlin, D. Scott Wilbur, PhD, Darrell R. Fisher, PhD, Mark D. Hylarides, PhD, Damian J. Green, MD, Ajay K. Gopal, MD, Ted Gooley, Oliver W. Press, MD, PhD, John M. Pagel, MD, PhD

Blood (2011) 118 (21): 3636.

https://doi.org/10.1182/blood.V118.21.3636.3636

Published: 2011

Journal Articles

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Ajay K. Gopal, MD, Ted Gooley, Joseph Rajendran, MD, John M. Pagel, MD, PhD, Darrell R. Fisher, PhD, David G. Maloney, MD, PhD, Frederick R. Appelbaum, MD, Andrew Shields, MD, Oliver W. Press, MD, PhD

Blood (2011) 118 (21): 663.

https://doi.org/10.1182/blood.V118.21.663.663

Published: 2011

Journal Articles

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

John M. Pagel, Aimee L. Kenoyer, Tom Bäck, Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Steven I. Park, Shani Frayo, Amanda Axtman, Nural Orgun, Johnnie Orozco, Jaideep Shenoi, Yukang Lin, Ajay K. Gopal, Damian J. Green, Frederick R. Appelbaum, Oliver W. Press

Blood (2011) 118 (3): 703–711.

https://doi.org/10.1182/blood-2011-04-347039

Published: 2011

Journal Articles

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Steven I. Park, Jaideep Shenoi, John M. Pagel, Don K. Hamlin, D. Scott Wilbur, Nural Orgun, Aimee L. Kenoyer, Shani Frayo, Amanda Axtman, Tom Bäck, Yukang Lin, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, Oliver W. Press

Blood (2010) 116 (20): 4231–4239.

https://doi.org/10.1182/blood-2010-05-282327

Published: 2010

NARROW

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody ( 90 Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies

Novel Bispecific Antibody Targeting CD45 and 90 Y-DOTA Is Effective Therapy for Acute Myeloid Leukemia in Preclinical Murine Models

Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase I Trial of 90 Y-BC8-DOTA (Anti-CD45) Monoclonal Antibody in Combination with Fludarabine and TBI As Conditioning for Allogeneic Peripheral Blood Stem Cell Transplant to Treat High Risk Multiple Myeloma

A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase I Study Of Myeloablative Radioimmunotherapy Using Iodine-131 Anti-CD45 Antibody Followed By Autologous Stem Cell Transplantation For High-Risk B-Cell and T-Cell Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Anti-CD45 radioimmunotherapy using 211 At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model

A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma

Anti-CD45 Radioimmunotherapy Using the Alpha-Emitting Radionuclide 211 At Combined with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model

Anti-CD45 Radioimmunotherapy Facilitates Donor Engraftment and Prolongs Survival in the Absence of TBI Prior to Haploidentical Bone Marrow Transplantation in a Disseminated Murine Leukemia Model

Conventional Anti-CD45 Radioimmunotherapy Comparing 90 Y or 177 Lu for Treatment of AML in a Syngeneic Disseminated Murine Leukemia Model,

A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only